Biopartners Receives European Union Marketing Authorisation for its Biosimilar Recombinant Human Growth Hormone - Valtropin®

08-May-2006
Biopartners has received marketing authorisation for the European Union from the European Commission for its biosimilar medicinal product Valtropin, a recombinant human growth hormone used for the treatment of human growth deficiency in children and Turner's Syndrome. Biopartners, jointly with LG Life Sciences, has co-developed a number of biopharmaceutical products including Valtropin and a sustained release formulation of Valtropin. Biopartners in-licensed Valtropin from LG Life Sciences and has commercialization rights for Valtropin in Europe, Japan and other parts of Asia. "We are delighted to have gained EU marketing authorisation for Valtropin" stated Mr Jean-Noël Treilles, CEO of Biopartners. "As the first product in our broad and advanced pipeline to gain authorisation, this marks a major milestone for Biopartners. We aim to make Valtropin available to healthcare professionals and patients through our distributors before the end of the year. Biopartners is currently developing a sustained release version of Valtropin that is currently in Phase III clinical trials."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances